Fax: (908) 231-7984
Epoetin alfa improves quality of life in patients with cancer
Results of a metaanalysis
Article first published online: 10 SEP 2004
Copyright © 2004 American Cancer Society
Volume 101, Issue 8, pages 1720–1732, 15 October 2004
How to Cite
Jones, M., Schenkel, B., Just, J. and Fallowfield, L. (2004), Epoetin alfa improves quality of life in patients with cancer. Cancer, 101: 1720–1732. doi: 10.1002/cncr.20569
- Issue published online: 1 OCT 2004
- Article first published online: 10 SEP 2004
- Manuscript Accepted: 8 JUL 2004
- Manuscript Revised: 30 JUN 2004
- Manuscript Received: 20 FEB 2004
- R. W. Johnson Pharmaceutical Research Institute (Raritan, NJ)
- epoetin alfa;
- quality of life
Anemia in patients with cancer causes fatigue, weakness, and impaired concentration, negatively impacting quality of life (QOL). In clinical trials involving patients with cancer who had varied characteristics, it has been shown that epoetin alfa treatment increased hemoglobin levels and improved QOL. A systematic review and metaanalysis of data from those trials was conducted to summarize existing knowledge on the role of epoetin alfa in improving QOL for anemic patients with cancer.
The Cochrane Library and other data bases were searched for published and unpublished, randomized/controlled and single-arm studies that included ≥ 20 patients with cancer per arm, epoetin alfa treatment, and QOL assessment by Cancer Linear Assessment Score (CLAS), Functional Assessment of Cancer Therapy (FACT) scale, Eastern Cooperative Oncology Group (ECOG) scale, and/or Medical Outcomes Study Short-Form 36 (SF-36) scale.
Among 11,459 patients from 23 trials, epoetin alfa and control cohorts were indistinguishable (with regard to demographic, clinical, QOL variables) at baseline. Epoetin alfa improved CLAS (20–25%), FACT-Fatigue (17%), and FACT-Anemia (12%) scores (P = 0.05). ECOG scores worsened for control cohorts (P = 0.05); epoetin alfa cohorts remained unchanged. Four of the SF-36 subscales, Physical Function, Role Physical, Vitality, and Social Function, improved with epoetin alfa (P = 0.05). Results adjusted for confounding factors remained consistent.
This metaanalysis confirmed that epoetin alfa improves QOL significantly in patients with cancer, emphasizing the need to manage anemia in this population. Cancer 2004. © 2004 American Cancer Society.
Anemia is a common problem in patients with cancer who receive chemotherapy.1–3 Despite the high prevalence of anemia in patients with cancer and the correlation of low hemoglobin levels and poor performance status, few patients with cancer receive treatment for anemia.4 Anemia and its effects interfere with effective treatment, which can lead to poorer clinical outcomes.5–8 One of the most common consequences associated with anemia is fatigue, which occurs in 58–90% of patients with cancer9–14 and can be more distressing and disruptive to ordinary activity even than disease-associated pain.10, 13, 15 Other common effects include exhaustion, weakness, and impaired concentration.5, 16–18 All of these factors have a negative impact on the quality of life (QOL) of patients with cancer.5, 10, 14 Patients who face disease-related debilitation and comorbidities present challenges as participants in rigorous clinical trials due to the difficulties of participating and the frequent presence of confounding factors15; the various anemia-associated symptoms and their respective roles in diminished QOL, for the most part, are understood poorly and have been under-investigated.5, 10, 14, 15
Recombinant human erythropoietin (epoetin alfa) is identical to human erythropoietin, which is a hematologic growth factor, and has been shown in clinical trials to correct and prevent anemia, decrease the need for blood transfusion, and improve the QOL of patients with cancer.7, 19–29 Recently, large trials involving patients receiving chemotherapy for cancer have demonstrated that the QOL benefits of epoetin alfa 150 IU/kg administered 3 times per week7, 26, 27 or 40,000 IU once weekly28 are related directly to the epoetin alfa-stimulated increase in red blood cell production.
The study described here is a metaanalysis of 23 randomized controlled trials (RCTs) and single-arm studies in which epoetin alfa was given to patients with cancer; QOL scores were measured throughout the study. Because the effect of this agent on QOL has not been accepted widely, and many patients who could benefit from anemia treatment do not receive it, this metaanalysis was designed to evaluate the role of epoetin alfa in improving QOL in patients receiving chemotherapy for cancer based on results of published and unpublished data.
MATERIALS AND METHODS
Search Strategy and Selection Criteria
MEDLINE®, EMBASE®, Ovid, the Cochrane Library, and Adis were searched for all articles published from 1985 to 2002, according to a written protocol. Articles with the following text words (tw) or Medical Subject Headings (MeSH®) in their titles, abstracts, or keyword lists were examined: erythropoietin (tw, MeSH), epoetin alfa (MeSH), epoetin (tw), Epogen (tw), Procrit® (tw), Eprex® (tw), epo (tw), anemia/drug therapy (MeSH, all subheadings), anemia/therapy (MeSH, all subheadings), or anemia/diet therapy (MeSH, all subheadings). Search results were limited to articles on human subjects indexed under the MeSH terms neoplasms or myelodysplastic syndromes (all subheadings). The data base search yielded 125 published abstracts. A number of unpublished internal reports were received directly from Johnson & Johnson Pharmaceutical Research and Development (Raritan, NJ).
Preliminary references were then examined to determine whether they met the inclusion criteria identified in the study protocol. Randomized control and single-arm, open-label studies of epoetin alfa with ≥ 20 patients per study group who were diagnosed with cancer, and/or who were receiving chemotherapy, and who reported ≥ 1 of the validated QOL measures that had been identified as being reported in sufficient studies were examined further. Only articles that met all of these inclusion criteria were accepted for this metaanalysis. In many cases, the full articles were retrieved to determine whether the acceptable QOL measures were reported. Articles in languages other than English were translated by a qualified translation service (Australian Institute of Modern Language, Waverley, New South Wales, Australia).
Health-Related QOL Scales
The study protocol was written to include a wide variety of QOL scales (some generic and some cancer-specific), which assessed factors including activity, fatigue, and energy that contribute to the decreased QOL experience of patients with cancer. A search was undertaken to include as many different QOL scales as possible. The QOL scales were included if results were reported in three or more references and if the scales were validated and in common usage. Four separate QOL scales were included that met these two criteria: the Cancer Linear Analog Scale (CLAS); the Functional Assessment of Cancer Therapy (FACT) scale; the Eastern Cooperative Oncology Group (ECOG) scale; and the Medical Outcomes Study Short Form-36 (SF-36) scale.
The CLAS and FACT scales were developed specifically to measure cancer QOL30 and constitute the primary variables in this metaanalysis. CLAS scores were reported as either CLAS or Linear Analog Scale Assessment (LASA) scores in the original reports; but they have been treated as equivalent in this metaanalysis, because they ask respondents (patients) to address the same question on the same recording instrument (a 100-mm line). The three CLAS subscales are 1) Activity; 2) Energy; and 3) Overall QOL. The FACT-General (FACT-G) has four subscales that measure physical, functional, emotional, and social well being and can be augmented by the use of other subscales (FACT-Fatigue [FACT-F], FACT-Anemia [FACT-An]) that measure fatigue and anemia, respectively. The ECOG scores are cancer-specific and were reported as either ECOG scores or World Health Organization (WHO) performance status scores in the original reports. A review of these two physician-reported scales indicated that they used the same anchors and were identical otherwise; hence, they have been treated as equivalent in this metaanalysis.31, 32 The SF-36 is a generic QOL patient questionnaire that is used widely in health-related research.33 Sufficient data were reported for eight SF-36 subscales to be reviewed: 1) Physical Function, 2) Role Physical, 3) Pain, 4) General Health, 5) Vitality, 6) Social Function, 7) Role/Emotion, and 8) Mental Health.
Data items were evaluated across publications to ensure that they were sufficiently common to warrant inclusion. Two surveyors independently extracted data onto a data-extraction form. The surveyors then compared data extractions and resolved any discrepancies by referral to the original publications. The data were then entered into a computer data base.
The primary objective of the metaanalysis was to compare QOL for patients receiving epoetin alfa with QOL for control patients. The three main analyses were 1) unadjusted, combined estimates of findings across studies; 2) estimates stratified by extraneous factors (study design, duration of treatment, life expectancy, tumor type, and chemotherapy type); and 3) estimates adjusted for differences among studies in demographics, clinical patient characteristics, or study design characteristics.
Each study arm contributed a cohort to the overall analyses. Therefore, a study with two epoetin alfa doses and a control group contributed three cohorts. Some heterogeneity in study design was encountered. Both single-arm and controlled trials were included, as noted above. Some of the controlled trials used a placebo control arm, whereas others used a no-treatment control arm. Both are treated as control cohorts in this metaanalysis.
Baseline demographics, clinical characteristics, and QOL were analyzed for epoetin alfa patients and control patients. Data on whether patients were receiving chemotherapy at the time of study entry were available at the cohort level rather than the patient level. The mean scores, 95% confidence intervals, and P values for homogeneity and publication bias were calculated.
The unadjusted changes in the mean QOL scores from prestudy testing to on-study testing was calculated for epoetin alfa patients and control patients. Like the baseline data, the mean scores, 95% confidence intervals, and P values for homogeneity and publication bias were calculated. Stratified analyses were then conducted to examine the effects of study design, duration of treatment, life expectancy, tumor stratum, and chemotherapy type on the mean QOL changes. Subsequently, two analyses were performed to assess the extent to which any changes in QOL were attributable to epoetin alfa. First, the response changes were adjusted for several potentially confounding factors (age, gender, baseline scores, study design, and duration of therapy) using regression analysis. Second, in a separate analysis, the QOL response to epoetin alfa therapy was adjusted directly to eliminate the placebo effect by subtracting the control response from the active therapy response in each study. The placebo (control) arms used in the analysis of placebo effect were drawn from any study that contained a nontreatment group, regardless of its experimental design.
Combined estimates were calculated when three or more cohorts were available. Simple combined estimates were formed using the DerSimonian and Laird approach.34 In very few instances, estimates of baseline mean or mean QOL responses were obtained without corresponding estimates of variance (standard deviation [SD] or standard error). In these instances, an SD was imputed from the mean of the known SDs. In a number of cases, the response data available were the mean and variance in a prestudy condition and after therapy. The within-patient variance in these cases could not be calculated directly and was approximated by assuming independence (i.e., variances were calculated, although two independent samples were involved).
Controlling for bias.
Controlling for potentially biasing factors was carried out both by stratification and by statistical modeling. Statistical models of metaregression were used as an adjunct to controlling for the potentially biasing effects of extraneous factors. A number of potentially confounding factors were chosen that were both relevant, a priori, and generally available from the reports obtained. The following potentially confounding factors were analyzed statistically: study design (RCT vs. other), mean age, gender, tumor stratum (solid vs. mixed or hematologic malignancy), duration of therapy (8–12 weeks vs. 16–30 weeks), and baseline mean of QOL parameter.
The extent to which studies yielded homogeneous estimates of response to therapy was assessed using the Cochrane test.34
Analysis of publication bias.
Analysis of publication bias was undertaken using the test described by Egger et al.35 The statistical test amounts to a nonparametric correlation of standardized effect size estimates correlated with their variances.
Overview of the Evidence Base
Based on a systematic data base search and literature review, 23 clinical trials that enrolled 11,459 patients were identified that fit the criteria for inclusion in this metaanalysis (Table 1). Each study arm was analyzed as a separate cohort, so that a single study could contribute multiple cohorts. Table 2 provides an overview of study characteristics for epoetin alfa cohorts and control cohorts. The distribution of tumor strata and duration of therapy did not differ markedly between the two groups. The majority of cohorts derived from studies in which all patients were receiving chemotherapy (79% of epoetin alfa cohorts and 77% of control cohorts). Note that, by definition, control cohorts could be drawn only from RCTs, whereas epoetin alfa cohorts were drawn from both RCTs and single-arm studies.
|Study identificationa||Study design||Double-blind?||QOL measures used||No. of patients enrolled||Percentage of total patients enrolled||Tumor stratum||Tumor stratum: specification|
|Ward H87-032, 87-014, 87-015b||RCT||Yes||CLAS, ECOG||24||1.1||Mixed||NA|
|Case et al, 199337||RCT||Yes||CLAS, ECOG||157||1.4||Mixed||Excluding acute leukemias and myeloid malignancies|
|Ludwig et al., 199338||OL||No||ECOG||67||0.6||Mixed||NA|
|Ludwig et al., 199338||OL||No||ECOG||34||0.3||Mixed||Multiple myeloma; squamous cell carcinoma|
|Henry et al., 199540||RCT||Yes||CLAS, ECOG||132||1.2||Mixed||Excluding acute leukemias and myeloid malignancies|
|Glaspy et al., 199726||OL||No||CLAS, ECOG||2342||20.4||Mixed||Nonmyeloid malignancies|
|Pawlicki et al., 199742||OL||No||CLAS||215||1.9||Mixed||NA|
|Demetri et al., 199827||OL||No||CLAS, FACT-An, FACT-An Total||2370||20.7||Mixed||Nonmyeloid malignancies|
|EPO-INT-27, 1998c||OL||No||CLAS, FACT-G, FACT-F, FACT-An, FACT-An Total, ECOG||39||0.3||Solid||NA|
|J89-040, 1999c||RCT||Yes||CLAS, ECOG, SF-36 (8 items)||221||1.9||Hem||Chronic lymphocytic leukemia|
|RWJ 22512, 1999c||RCT||Yes||CLAS, ECOG, SF-36 (8 items)||45||0.4||Hem||Chronic lymphocytic leukemia|
|Thatcher et al., 199943||RCT||No||CLAS, ECOG||130||1.1||Solid||Small cell lung carcinoma|
|Davies, 200044||RCT||No||CLAS, FACT-An Total, ECOG, NHP (6 items)||120||1.0||Solid||NA|
|Dammacco et al., 200144||RCT||Yes||CLAS, ECOG, NHP (6 items)||145||1.3||Hem||Multiple myeloma|
|Gabrilove et al., 200128||OL||No||CLAS, FACT-F, FACT-An, ECOG||3012||26.3||Mixed||Nonmyeloid malignancy|
|Littlewood et al., 20017||RCT||Yes||CLAS, FACT-G, FACT-F, FACT-An, FACT-An, Total, ECOG, SF-36 (8 items)||375||3.3||Mixed||Solid or nonmyeloid hematologic malignancy|
|McAdams, 2001c||RCT||No||FACT-An Total, ECOG||95||0.8||Solid||NA|
|Quirt et al., 200145||OL||No||CLAS, FACT-G, FACT-F, FACT-An, FACT-An Total, ECOG||401||3.5||Mixed||Nonmyeloid malignancy|
|Wilkinson et al., 200146||RCT||No||CLAS, FACT-F, FACT-An Total, ECOG||182||1.6||Solid||Ovarian|
|Chang and Couture, 200347||RCT||No||CLAS, FACT-F, FACT-An||138||1.2||Solid||NA|
|Granetto et al., 200348||RCT||No||CLAS, ECOG||546||4.8||Mixed||NA|
|Feature||No. of cohorts (%)||P value|
|Total cohorts included in analysis||28||13||—|
|RCT design||18 (64)||13 (100)||—|
|Double-blind||8 (29)||8 (62)||0.04|
|Advanced disease||4 (50)||4 (100)||0.08|
|Baseline anemica||25 (93)||12 (92)||> 0.9|
|Solid tumors||9 (32)||5 (38)||0.4|
|Mixed solid/hematologic tumors||16 (57)||5 (38)||0.4|
|Epoetin Alfa therapy for 8–12 weeks||12 (43)||8 (62)||0.3|
|Epoetin Alfa therapy for 16–30 weeks||16 (57)||5 (38)||0.3|
Overall, baseline demographic and clinical characteristics for epoetin alfa-treated and control patients were similar (Table 3). The percentage of females in the control group was slightly greater compared with percentage of females in the epoetin alfa group, but the difference was not statistically significant. This slight difference may have been due, in part, to the fact that the 3 large, community-based studies,26–28 which contributed 67% of patients to the metaanalysis, included lower proportions of females than most of the trials. Table 3 also reports the baseline mean QOL scores for both treatment groups. Note that where it is indicated that data were not available, it is possible that either that no data were reported or that fewer than three cohorts reported this factor. Although they did not differ significantly, mean baseline CLAS and FACT scores (with the exception of the FACT-An Total) were consistently lower for epoetin alfa-treated patients compared with control patients (Table 3). The FACT-An subscale score was > 6 points lower for the epoetin alfa-treated patients at baseline compared with the control patients. These scores were influenced heavily by the three community-based studies, which had patients with lower QOL scores at study entry.26–28 Twenty studies reported baseline ECOG scores that were similar in epoetin alfa-treated and control patients. The SF-36 scores also were included in the metaanalysis, even though only three studies (Littlewood et al.7 and unpublished data) contributed SF-36 subscale data. The baseline SF-36 scores were nearly identical (Table 3).
|Characteristic||Epoetin Alfa cohorts||Control cohorts|
|Studiesb||Value||95% CI||P value||Studiesb||Value||95% CI||P value|
|Mean age (yrs)||7,24–28, 36,37,40–48c||59.6||58.3–60.8||< 0.001||0.004||7,24,25,36,37,40,41,43,44,46,47c||61.1||58.4–63.9||< 0.001||0.8|
|Female||7,24–28, 36–48c||64.2||61.4–67.0||< 0.001||0.5||7,24,25,36,37,40,41,43,46,47c||73.8||65.0–81.1||< 0.001||0.07|
|Disease duration (mos)||7,44,45,47c||30.0||20.2–39.8||< 0.001||0.006||7,43,44,47c||38.1||28.5–47.7||0.001||0.3|
|Hemoglobin concentration (g/dL)||7,26–28, 42–48c||9.9||9.7–10.2||< 0.001||0.03||7,43,44,46,47c||10.3||9.6–11.0||< 0.001||0.8|
|Hematocrit (%)||7,24–28,36, 37,40–44,48c||29.9||29.3–30.6||< 0.001||0.01||7,24,25,36,37, 40,41,43,44,46c||30.0||28.1–32.0||< 0.001||> 0.9|
|Derived hematocrit (%)||7,24–28,36, 37,40–48c||29.9||29.3–30.5||< 0.001||0.007||7,24,25,36,37, 40,41,43,44,46,47c||30.4||28.7–32.2||< 0.001||0.4|
|Activity||7,268–28,37, 40,42,45–48c||44.7||42.9–46.6||< 0.001||0.001||7,24,25,36,37, 40,41,43,44,46,47c||48.2||44.08–52.3||< 0.001||0.5|
|Energy||7,26–28,37, 40,42,44,45–48c||43.7||42.0–45.4||< 0.001||0.001||7,24,25,36,37, 40,41,43,44,46,47c||47.0||42.6–51.4||< 0.001||0.3|
|Total QOL||7,26–28,37, 40,42,44,45–48c||48.9||47.4–50.4||< 0.001||0.009||7,24,25,36,37, 40,41,43,44,46,47c||52.9||49.3–56.6||< 0.001||0.7|
|Anemia Total||7,27,45,46c||114.7||104.3–125.1||< 0.001||0.5||7,46c||113.1||90.3–135.8||< 0.001||0.4|
|ECOG||7,24–26,28,36–38,40, 41,43–46,48c||1.15||1.03–1.26||< 0.001||0.05||7,24,25,36,37, 40,41,43,44c||1.05||0.91–1.19||< 0.001||0.8|
|Physical Function||7c||52.8||5.0–55.7||0.8||0.01||7c||49.4||45.6–53.2||0.5||> 0.9|
|Role Emotion||7c||54.8||50.3–59.4||> 0.9||0.2||7c||54.5||37.9–71.0||0.002||0.7|
Many of the baseline mean values showed statistically significant heterogeneity in the results for both the epoetin alfa-treated and control cohorts (Table 3). Tests of publication bias for baseline conditions were conflicting. There was little evidence of publication bias in control cohort baseline results, but there were scattered suggestions of bias in epoetin alfa cohort baseline results.
Effect of Epoetin Alfa Treatment on QOL Mean Change Scores
Overview of effect.
The metaanalysis of the 23 trials showed a clinically and statistically significant beneficial effect of epoetin alfa in improving the QOL of patients according to a number of scales (sample sizes are provided in Table 4). Most of the subscales analyzed showed that QOL scores improved for patients who received epoetin alfa but not for control patients (Table 5). The most definitive results were seen in the cancer-specific subscales focused on anemia (Energy and Vitality). When the large studies by Glaspy et al.,26 Demetri et al.,27 and Gabrilove et al.28 were removed, the improvement in QOL scores remained statistically significant. When QOL scores were adjusted for confounding factors and placebo effects, the results remained statistically significant (P < 0.05).
|Parameter||Control cohort||Epoetin alfa cohort|
|CLAS Overall QOL||567||7212|
|Subscale||Epoetin Alfa cohorts||Control cohorts|
|Studiesa||Score||95% CI||P value||Studiesa||Score||95% CI||P value|
|Activity||7,26–28,37,40, 42,45,46,48b||10.3||8.8–11.8||< 0.001||0.2||7,24,25,36,37,40, 44–47b||−0.004||−2.6–2.6||0.3||0.3|
|Energy||7,26–28,37,40, 42,45,46,48b||10.4||8.7–12.0||< 0.001||0.06||7,24,25,36,37,40, 44–47b||1.4||−1.8–4.||0.03||0.5|
|Total QOL||7,26–28,37,40, 42,45,46,48b||9.0||7.3–10.7||< 0.001||0.5||7,24,25,36,37, 40,41,44–47b||−1.6||−4.1–0.9||0.2||0.06|
|Anemia||7,27,28,45,47b||5.3||4.4–6.1||0.08||0.4||1,11||−2.7||−4.8 to −0.6||> 0.9||—|
|Anemia Total||7,27,45,46b||7.3||4.7–9.8||< 0.001||0.9||7,45,46b||1.2||−2.5–5.0||0.008||0.5|
|ECOG||7,24–6,28,36–38, 40,41,43–46,48b||0.07||−0.02–0.16||< 0.001||0.001||7,24,25,36,37, 40,41,43,44,46b||0.18||0.02–0.34||0.002||0.9|
|Physical Function||7, 44b||3.5||0.6–6.5||0.6||0.9||7, 44b||−1.7||−5.7–2.2||0.5||0.5|
|Role Physical||7, 44b||11.0||6.3–15.7||0.8||0.1||7, 44b||3.2||−2.5–9.0||0.4||0.4|
|Pain||7, 44b||3.1||−0.3–6.4||0.4||> 0.9||7, 44b||1.4||−3.3–6.0||0.5||0.7|
|General Health||7, 44b||1.1||−2.6–4.8||0.3||0.2||7, 44b||−0.05||−5.1–5.0||0.3||0.4|
|Vitality||7, 44b||5.8||3.2–8.4||0.7||0.3||7, 44b||−2.5||−5.9–0.8||0.6||0.6|
|Social Function||7, 44b||5.0||1.6–8.5||> 0.9||0.7||7, 44b||−3.2||−8.6–2.2||0.4||0.3|
|Role Emotion||7, 44b||5.4||−0.2–11.0||0.7||0.3||7, 44b||5.9||−2.2–13.9||0.7||> 0.9|
|Mental Health||7, 44b||3.7||1.6–5.9||0.8||0.8||7, 44b||0.5||−2.4–3.4||0.6||0.4|
Unadjusted QOL subscale mean change scores.
There was a clear and positive improvement in the mean change from baseline scores for the three CLAS subscales in epoetin alfa–treated patients (Fig. 1). The improvement from baseline was significant (P < 0.05) and substantial (20–25%) (Table 5). Similarly, the epoetin alfa-treated patients experienced statistically significant improvements (P < 0.05) in the mean change from baseline scores for the FACT subscales, whereas the scores for control patients remained unchanged or worsened (Fig. 2). The biggest FACT subscale changes in the epoetin alfa-treated patients were in the FACT-F (17%) and the FACT-An (12%). The ECOG mean change scores did not differ significantly for epoetin alfa-treated patients. However, the control patients worsened significantly (P < 0.05) on this scale (an increase represents decreased QOL). Four SF-36 subscales (Physical Function, Role Physical, Vitality, and Social Function) improved significantly in the epoetin alfa patients (P < 0.05).
There was significant heterogeneity in the QOL mean change scores for many of the epoetin alfa QOL subscales and for some of the control group QOL subscales. There was no suggestion of publication bias in the estimates of response in QOL in either epoetin alfa cohorts or control cohorts. This stands in contrast to the earlier finding of some suggestion of bias in epoetin alfa baseline results. Because the response to therapy is the key outcome, the bias in the baseline scores, although noteworthy, is not considered crucial.
Stratification analyses of unadjusted QOL mean change scores.
The mean change in QOL results was stratified by trial design. Improvements in CLAS data in the epoetin alfa group were statistically significant for both double-blind and open-label/single-arm studies (P < 0.05), with the biggest improvements seen in the open-label/single-arm studies.26–28 This is because the 3 large, community-based studies demonstrated mean increases ≥ 10 points on each of these subscales, whereas the trials had a range of mean changes but a lower overall mean change for each of these scales. The other QOL scales were not stratified by trial design, because the distribution of designs used in the analyses for these scales was not varied.
The mean change in QOL results also was stratified by duration of epoetin alfa treatment. It is unlikely that QOL improves immediately with improved red blood cell production; hence, longer duration of therapy may be expected to produce greater responses in QOL. The studies that applied longer duration of epoetin alfa treatment tended to report larger increases in CLAS subscale scores, indicating that longer treatment with epoetin alfa brings about a cumulative increase in QOL. There was not enough FACT data for shorter studies to compare the response with longer studies. It is noteworthy that ECOG scores increased significantly for the longer studies (P < 0.05), representing a decline in performance status; whereas the increase remained statistically insignificant for the shorter studies. This indicates that there is a decrease in performance status over time in patients receiving chemotherapy for cancer.
The mean change in QOL results was stratified by life expectancy, because stage of disease was unavailable for half of the studies. This is considered potentially important, because chemotherapy may outweigh anemia therapy at some stages of some cancers. According to the change in CLAS scores, the patients in trials that selected participants with longer life expectancies experienced slightly greater increases in QOL. The FACT-An Total score increased significantly for the studies in patients with longer life expectancies (P < 0.05), whereas the increase was not statistically significant in the studies that included patients with shorter life expectancies. The ECOG scores did not change significantly in patients with shorter life expectancies, but ECOG scores increased (QOL deteriorated) significantly in studies that included patients with longer life expectancies (P < 0.05).
Stratification by tumor stratum also was conducted. The CLAS subscale scores improved significantly for both patients with solid tumors and patients with hematologic malignancies (P < 0.05). The FACT-An Total score improved to a statistically significant extent only in the studies that included hematologic malignancies (P < 0.05). The ECOG scores did not change significantly by tumor stratum.
The mean change in QOL scores also was stratified by chemotherapy type. Platinum-based versus nonplatinum-based chemotherapy agents often are discussed with regard to their differential impacts on QOL. Studies of patients who only received platinum-based chemotherapy did not have QOL results that differed substantively from the studies that included patients who received nonplatinum-based chemotherapy. However, the change in FACT-An Total score was statistically significant in the studies that included nonplatinum-based chemotherapy (P < 0.05), whereas the mean change scores for the platinum-only studies were positive but were not statistically significant.
Analysis for potentially confounding factors.
It was found that patients in the epoetin alfa cohorts and control cohorts generally were similar in terms of baseline characteristics. However, a combination of subtle differences between cohorts over a number of parameters cumulatively may lead to differences of some importance. Table 6 compares the QOL results after adjusting for a number of preselected factors (described above) with unadjusted results. The results of this analysis suggest that baseline factors did not confound the comparison of epoetin alfa cohorts and control cohorts. This was true of CLAS, FACT, and ECOG QOL measures. SF-36 results were not included in this analysis, because those data were noncancer-specific and were not as robust as the CLAS and FACT data: Only 3 of the studies that were included reported SF-36 results.
|QOL measure||Adjusted difference (95% CI)||Unadjusted difference (95% CI)|
|Age and gender||Age, gender, and baseline score||Age, gender, baseline score, trial design (RCT vs. other), and duration of epoetin alfa therapy (16–30 weeks vs. 8–12 weeks)|
|Activity||9.9 (6.4–13.5)||9.5 (5.9–13.1)||8.5 (5.2–11.8)||7.3 (4.3–10.3)|
|Energy Levels||8.7 (4.8–12.6)||8.4 (4.4–12.5)||6.9 (3.2–10.7)||5.8 (2.3–9.3)|
|Overall QOL||1.0 (6.0–14.0)||9.3 (5.5–13.1)||7.7 (4.1–11.3)||7.7 (5.1–10.4)|
|FACT Total||6.2 (0.6–11.7)||6.5 (−0.2–13.1)||5.4 (3.4–7.3)||4.2 (2.1–6.4)|
|ECOG||−0.1 (−0.3–0.1)||−0.1 (−0.3–0.1)||−0.1 (−0.3–0.1)||−0.1 (−0.3–0.0)|
Analysis of placebo effects on QOL mean change scores.
This analysis was conducted to estimate the degree of response of epoetin alfa-treated patients that is greater than can be accounted for by the placebo effect. These estimates were obtained by removing the control responses from the active therapy responses in each study that contained a nontreatment group, regardless of the study's experimental design. Subtracting the placebo response confirmed that the change in the CLAS subscales was substantial and statistically significant (P < 0.05). Similarly, the change in the FACT-F and FACT-An subscales also was statistically significant (P < 0.05) after adjusting for placebo. However, the FACT-An Total change was not statistically significant, although the change was positive. ECOG scores did not change significantly after adjusting for placebo effects. Confirming the disease-specific and general QOL benefits seen in the CLAS and FACT results, all but 1 of the 8 SF-36 subscales changed in a positive direction, with 5 subscales (Physical Function, Role Physical, Vitality, Social Function, and Mental Health) showing statistically significant improvements (P < 0.05). The Physical Function, Role Function, and Vitality subscales are of particular interest, because these subscales would be expected, a priori, to improve with anemia correction.
There was no suggestion of publication bias in the placebo-adjusted estimates of response to therapy for any parameter. It also is important to note that, although the unadjusted estimates of QOL response exhibited substantial between-study variance, there was considerable homogeneity once placebo effects were removed. Thus, it appears that the effect of epoetin alfa is strong despite the heterogeneity in the sample populations.
In patients with cancer who are receiving chemotherapy, the impact of both the disease and the treatment can be severe. A common effect of cancer therapy is anemia, which is associated with a substantial decrease in patient QOL. The results of clinical trials have demonstrated that epoetin alfa corrects cancer-related anemia and significantly improves QOL in patients with cancer who are receiving chemotherapy.7, 27, 28, 49 The objective of the current metaanalysis was to evaluate the published and available unpublished data on the impact of epoetin alfa on QOL in patients with cancer who were or were not receiving chemotherapy.
The current study identified a significant positive effect of epoetin alfa on QOL, as measured with a variety of scales. There was a clear difference in QOL between epoetin alfa cohorts and control cohorts. It is noteworthy that the difference was most substantial in the QOL scales for which the effect of epoetin alfa would be expected a priori. In the CLAS Activity and Energy subscales, for example, the average responses for the epoetin alfa cohorts were 25% better than baseline scores, whereas the responses for the control cohorts were ± 3% compared with baseline responses. Similarly, epoetin alfa-treated cohorts improved by an average of 15% on the SF-36 Vitality subscale, compared with a 5% decrease for control cohorts. The results of the metaanalysis were upheld after adjusting for several confounding factors, indicating that epoetin alfa therapy has a direct effect on QOL in patients with cancer.
Although the effect of epoetin alfa was consistent across different studies, there was evidence of considerable variation between studies with respect to the magnitude of the response. This was evident in the significant heterogeneity for most QOL scales. The estimates of response in QOL parameters were largest in single-arm/open-label studies, which were dominated by three large, community-based studies that had among the largest estimates of the effect of epoetin alfa. The duration of epoetin alfa therapy also was an apparent factor. The degree of response increased with the length of the study and was associated with a greater increase in QOL. However, after adjusting for placebo effect, considerable homogeneity was seen in QOL response.
Stratification of mean QOL change results by life expectancy showed that, for FACT-An (P < 0.05) and possibly for CLAS, patients in trials that selected participants with longer life expectancies experienced greater increases in QOL. In contrast, ECOG scores showed QOL deterioration in studies that included patients with longer life expectancies (P < 0.05). Patients who are at the end stage of their disease generally will have the greatest deterioration in their QOL and, thus, also have the greatest capacity to improve their QOL scores. Because CLAS and other QOL scales measure overall physical and mental well being, there is a greater potential for patients to improve these scores. However, ECOG measures only physical well being, and patients at the end stage of cancer have little capacity to improve physically. In contrast to the FACT-F scale, any improvements in fatigue are not expected to be detected by ECOG. In addition, in contrast to the CLAS, FACT, and SF-36 instruments, which are self-reported by patients, the ECOG/WHO scale is recorded by clinicians. Studies have shown that physicians and patients differ in their perceptions of the extent to which anemia-associated symptoms, such as fatigue, adversely affect patients' daily lives.10 Therefore, due to physician reporting, ECOG-derived and WHO-derived data may understate somewhat the difference between cohorts receiving epoetin alfa treatment and untreated cohorts.
There was no clear evidence of publication bias, suggesting that the results represent a reasonable view of the evidence available. However, it is noteworthy that the quantity of data available varied substantially for different QOL scales. Hence, the depth of data used to draw conclusions is variable but apparently unbiased.
Despite some variations in statistical significance, the results of this metaanalysis show that epoetin alfa significantly improves QOL for patients with cancer, irrespective of chemotherapy use. Specifically, epoetin alfa significantly improved QOL using scales that focus on cancer and anemia. With the exception of the FACT-An Total, all FACT subscales (FACT-G, FACT-F, and FACT-An), as well as the CLAS subscales for Energy and Activity and the SF-36 Vitality subscales, showed substantial improvement for epoetin alfa-treated patients, but not for control patients. When the data were adjusted for confounding factors and placebo effect, the epoetin alfa-treated cohorts continued to show significant improvements in QOL. Based on these comprehensive results, epoetin alfa is an effective therapy that improves QOL for patients with cancer.
- 4European Cancer Anaemia Survey (ECAS): prospective evaluation of anemia in over 15,000 cancer (CA) patients (pts) [abstract]. Ann Oncol. 2002; 13( Suppl 5): 169., , , .
- 31Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chron Dis. 1960; 11: 7–33., , , et al.
- 45Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. Canadian Eprex Oncology Study Group. J Clin Oncol. 2001; 19: 4126–4134., , , et al.
- 46Early intervention with epoetin alfa treats anaemia and improves quality of life in ovarian cancer patients undergoing chemotherapy [abstract]. Eur J Cancer. 2001; 37(6 Suppl ): S264., , , .
- 47Once weekly epoetin alfa maintains hemoglobin, improves quality of life and reduces transfusion in breast cancer patients receiving chemotherapy. Canadian Eprex Study Group [abstract]. Proc Am Soc Clin Oncol. 2003; 22: 727., .